Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eligo Presents Preclinical Data Showing Gut Microbiome Modulation via Delivery of CRISPR Nuclease Impacts Disease Progression","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Eligo Bioscience"},{"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem and the Crohn\u2019s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of A New Therapeutic Approach in Inflammatory Bowel Disease (IBD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Inotrem"},{"company":"Enterome","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.7 million","newsHeadline":"Enterome Signs Major Strategic R&D Collaboration with Nestl\u00e9 Health Science to Develop and Commercialize New AllerMimics\u2122 and EndoMimics\u2122 Immunotherapies for Food Allergies and Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Enterome"}]

Enterome

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enterome Signs Major Strategic R&D Collaboration with Nestlé Health Science to Develop and Commercialize New AllerMimics™ and EndoMimics™ Immunotherapies for Food Alle...

Details:

Enterome and Nestlé Health Science will co-develop Enterome’s lead EndoMimics™ compound, EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD). EB1010 is due to enter clinical trials in 2023.

Lead Product(s): EB1010

Therapeutic Area: Gastroenterology Product Name: EB1010

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Undisclosed Upfront Cash: $40.7 million

Deal Type: Collaboration July 18, 2022

ASK
US

Upload
your Pipeline Activity

Inotrem

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of A New Therapeutic Approach in Inflammatory Bowel Disease (IB...

Details:

The objective of the R&D collaboration is to confirm the relationship between the activation of the TREM-1 pathway and the severity and progression of IBD in patients, with the ultimate intention of developing a new treatment.

Lead Product(s): Monoclonal Antibody

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Crohn’s & Colitis Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 14, 2022

ASK
US

Upload
your Pipeline Activity

Eligo Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Eligo Presents Preclinical Data Showing Gut Microbiome Modulation via Delivery of CRISPR Nuclease Impacts Disease Progression

Details:

The data presented at the CRISPR meeting continues to support the potential of our lead candidate EB003 and use of the Eligobiotics® platform to modulate bacterial populations of microbiome for treatment of severe diarrhea induced by shiga-toxin.

Lead Product(s): EB003

Therapeutic Area: Gastroenterology Product Name: EB003

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY